Scholarlink

Background <p>Racial and ethnic breast cancer disparities persist. This may be reflected by differences in Oncotype DX recurrence scores (RS), which are higher for Black women. This study assesses the association between ancestry and RS.</p> Methods <p>Stage I–III hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with ancestry and RS data were prospectively identified from 2017 to 2021. RS were grouped into low, intermediate, and high categories. Multinomial regression determined the association between ancestry and RS controlling for ancestry and estrogen receptor (ER), progesterone receptor (PR), and HER2 expression.</p> Results <p>Of 174 patients,&#xa0;28 (16.1%) self-identified as non-Hispanic White, 107 (61.5%) self-identified as Hispanic White, 19 (10.9%) self-identified as non-Hispanic Black, and 9 (5.2%) self-identified as Hispanic Black. Ninety-four (54.0%) patients had low RS, 51 (29.3%) had intermediate RS, and 29 (16.7%) had high RS. On multivariable analyses, West African ancestry was associated with increased odds of intermediate (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.00–1.04, <i>p</i>&#xa0;=&#xa0;0.039) and high (OR 1.03, 95% CI 1.00–1.06, <i>p</i>&#xa0;=&#xa0;0.022) RS. East Asian ancestry was associated with decreased odds of intermediate RS (OR 0.78, 95% CI 0.60–1.00, <i>p</i>&#xa0;=&#xa0;0.048). Increasing ER (OR 0.43, 95% CI 0.23–0.82, <i>p</i>&#xa0;=&#xa0;0.011), PR (OR 0.20, 95% CI 0.11–0.34, <i>p</i>&#xa0;&lt;&#xa0;0.001), and HER2 (OR 0.24, 95% CI 0.09–0.63, <i>p</i>&#xa0;=&#xa0;0.004) expression were associated with lower odds of high RS.</p> Conclusion <p>Increasing West African ancestry is associated with increased odds of high and intermediate RS, while increasing East Asian ancestry is associated with lower odds of intermediate RS. These findings require validation but suggest ancestry may represent a biological biomarker and that assays guiding adjuvant therapy may require ancestry-based calibration in HR+/HER2− tumors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic Ancestry and 21-Gene Oncotype DX Breast Cancer Recurrence Scores

  • 期刊论文

  • 发表日期：

    2025年2月27日

查看全文
  • Peter A. Borowsky,
  • Alexandra E. Hernandez,
  • Susan B. Kesmodel,
  • Neha Goel

摘要

Background

Racial and ethnic breast cancer disparities persist. This may be reflected by differences in Oncotype DX recurrence scores (RS), which are higher for Black women. This study assesses the association between ancestry and RS.

Methods

Stage I–III hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with ancestry and RS data were prospectively identified from 2017 to 2021. RS were grouped into low, intermediate, and high categories. Multinomial regression determined the association between ancestry and RS controlling for ancestry and estrogen receptor (ER), progesterone receptor (PR), and HER2 expression.

Results

Of 174 patients, 28 (16.1%) self-identified as non-Hispanic White, 107 (61.5%) self-identified as Hispanic White, 19 (10.9%) self-identified as non-Hispanic Black, and 9 (5.2%) self-identified as Hispanic Black. Ninety-four (54.0%) patients had low RS, 51 (29.3%) had intermediate RS, and 29 (16.7%) had high RS. On multivariable analyses, West African ancestry was associated with increased odds of intermediate (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.00–1.04, p = 0.039) and high (OR 1.03, 95% CI 1.00–1.06, p = 0.022) RS. East Asian ancestry was associated with decreased odds of intermediate RS (OR 0.78, 95% CI 0.60–1.00, p = 0.048). Increasing ER (OR 0.43, 95% CI 0.23–0.82, p = 0.011), PR (OR 0.20, 95% CI 0.11–0.34, p < 0.001), and HER2 (OR 0.24, 95% CI 0.09–0.63, p = 0.004) expression were associated with lower odds of high RS.

Conclusion

Increasing West African ancestry is associated with increased odds of high and intermediate RS, while increasing East Asian ancestry is associated with lower odds of intermediate RS. These findings require validation but suggest ancestry may represent a biological biomarker and that assays guiding adjuvant therapy may require ancestry-based calibration in HR+/HER2− tumors.